Literature DB >> 5081602

Daunorubicin metabolism in acute nonlymphocytic leukemia.

D H Huffman, R S Benjamin, N R Bachur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5081602     DOI： 10.1002/cpt1972136895

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  18 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

Review 2.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

3.  Uptake and metabolism of daunorubicin by human myelocytic cells.

Authors:  G Vasanthakumar; N K Ahmed
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 5.  Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure.

Authors:  D E Drayer
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

6.  Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerases.

Authors:  M F Goodman; M J Bessman; N R Bachur
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

7.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

8.  Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.

Authors:  D L de Valeriola; D D Ross; A Forrest; D P Cuddy; M J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Authors:  Federico Pea; Domenico Russo; Mariagrazia Michieli; Daniela Damiani; Renato Fanin; Angela Michelutti; Teresa Michelutti; Stefano Piccolrovazzi; Michele Baccarani; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.